Published in

Oxford University Press, The American Journal of Clinical Nutrition, 5(91), p. 1402-1407, 2010

DOI: 10.3945/ajcn.2009.28981

Links

Tools

Export citation

Search in Google Scholar

Effect of Alzheimer disease genetic risk disclosure on dietary supplement use

Journal article published in 2010 by Jacqueline A. Vernarelli, J. Scott Roberts, Susan Hiraki, Clara A. Chen, L. Adrienne Cupples ORCID, Robert C. Green
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background: Genetic susceptibility testing for Alzheimer disease (AD) with APOE genotype disclosure is not recommended for clinical use but is available through direct-to-consumer (DTC) genetic testing companies. Little is known about whether APOE genotype disclosure would actually prompt changes in nutrition behaviors among at-risk individuals.